Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12620001352998
Ethics application status
Approved
Date submitted
12/11/2020
Date registered
15/12/2020
Date last updated
21/01/2022
Date data sharing statement initially provided
15/12/2020
Date results information initially provided
21/01/2022
Type of registration
Retrospectively registered
Titles & IDs
Public title
VIS649-102: A study assessing single doses of VIS649, in healthy adults.
Query!
Scientific title
VIS649-102: A sequential treatment, phase 1, open-label study to assess the pharmacokinetics, safety and tolerability, and pharmacodynamics of VIS649 solution administered subcutaneously in healthy male and female participants aged 18 to 55 years.
Query!
Secondary ID [1]
302507
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Immunoglobulin A Nephropathy
319371
0
Query!
Condition category
Condition code
Renal and Urogenital
317342
317342
0
0
Query!
Kidney disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Participants will receive a single dose of VIS649 administered via subcutaneous injection by the investigator. Group 1 will receive 200 mg VIS649, Group 2 will receive 400 mg VIS649, Group 3 will receive 400 mg VIS649 and Group 4 will receive 600 mg VIS649.
Query!
Intervention code [1]
318799
0
Treatment: Drugs
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
325376
0
Pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of VIS649 including Cmax, AUC0-inf, and AUC0-last as determined through measurement of circulating serum VIS649 levels.
Query!
Assessment method [1]
325376
0
Query!
Timepoint [1]
325376
0
PK samples will be collected at 4 and 8 hours after receiving a single dose and then on days 2, 3, 5, 7, 9, 14, 28, 42, 56, 70, 84, 112 (End of study visit) post-dose.
Query!
Primary outcome [2]
325377
0
Characterize the safety and tolerability of VIS649 administered as a single SC dose as assessed by physical examination; recording vital signs (blood pressure, pulse, respiratory rate and oral temperature); clinical laboratory tests (serum chemistry, hematology and urinalysis); assessment of injection site pain from the Visual Analog Scale; and adverse events self-reported by the participant.
Query!
Assessment method [2]
325377
0
Query!
Timepoint [2]
325377
0
16 weeks post VIS649 administration
Query!
Secondary outcome [1]
387713
0
Pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of VIS649 as determined through measurement of circulating serum VIS649 levels. The parameters measured will be:
Clast (time of last serum concentration),
tmax (time of maximum serum concentration),
tlast (time of last quantifiable observed concentration)
t1/2 (apparent terminal elimination half-life),
AUC0-28d (area under the concentration-time curve from day 0 to day 28),
AUC0-112d (area under the concentration-time curve from day 0 to day 112),
%AUCex (Percentage of AUC0-inf obtained by extrapolation);
Vd/F (apparent volume of distribution),
CL/F (apparent clearance).
Query!
Assessment method [1]
387713
0
Query!
Timepoint [1]
387713
0
PK samples will be collected at 4 and 8 hours after receiving a single dose and then on days 2, 3, 5, 7, 9, 14, 28, 42, 56, 70, 84, 112 (End of study visit) post-dose.
Query!
Eligibility
Key inclusion criteria
Healthy males and females between 18 and 55 years of age (inclusive)
Body mass index (BMI) 17 - 32 kg/m2, inclusive
Willing to adhere to study rules and restrictions
Willing to follow contraception requirements
Capable of giving informed consent
Pass all screening assessments (WBC and platelets count; hemoglobin; eGFR; serum creatinine; glucose; serum IgG, IgM and IgA levels;
Willing and able to comply with study restrictions and to remain at the study site for the in-patient duration of the study and return for all follow-up visits
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
55
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Female participants who are pregnant or breastfeeding.
Participant has a history or current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, hematologic, autoimmune, blood dyscrasias or other medical disorder including psychiatric disorders, cirrhosis, or malignancy.
Participant has a history or presence of proteinuria, chronic kidney disease, disease requiring immunosuppressive therapy or is considered to be immunosuppressed for any reason.
History of a previous severe allergic reaction with generalized urticaria; angioedema or anaphylaxis.
Known hypoglobulinemia disorder.
History of chronic infection or any infection requiring hospitalization or treatment within 30 days.
Received vaccination in prior 30 days
Alanine transaminase (ALT) or aspartate transaminase (AST) >1.5 x ULN; total bilirubin .1.5 x ULN.
Known hepatic or biliary abnormalities
A QT interval corrected for heart rate using Fridericia's correction (QTcF) .450 msec for males or >470 msec for females.
Previous receipt of antibody or biologic therapy
Concomitant use of marketed or investigational systemic immunosuppressive or immunomodulatory medications is prohibited and requires a a washout period prior to screening.
Is participating in another clinical study of any investigational drug, device or intervention within the last 30 days or 5 half-lives of the intervention, whichever is longer.
Meets required diagnostic assessments for blood pressure, presence of hepatitis B surface antigen, chronic hepatitis C infection, presence of hepatitis B core antibody, known history of positive human immunodeficiency virus, positive urine drug or alcohol breath screen at screening or Day -1.
Male who consumes more than 15 standard alcohol drinks per week or female who consumes more than 10 standard alcohol drinks per week.
Participant who has donated >500 ml of blood within 7 days prior to baseline.
Is an employee of the clinical research team.
Participant judged by the primary investigator or the medical monitor to be inappropriate for the study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
7/12/2020
Query!
Date of last participant enrolment
Anticipated
15/02/2021
Query!
Actual
6/04/2021
Query!
Date of last data collection
Anticipated
15/06/2021
Query!
Actual
26/07/2021
Query!
Sample size
Target
48
Query!
Accrual to date
Query!
Final
48
Query!
Recruitment outside Australia
Country [1]
23052
0
New Zealand
Query!
State/province [1]
23052
0
Query!
Funding & Sponsors
Funding source category [1]
306939
0
Commercial sector/Industry
Query!
Name [1]
306939
0
Visterra, Inc.
Query!
Address [1]
306939
0
275 2nd Avenue
Waltham, MA 02451
United States of America
Query!
Country [1]
306939
0
United States of America
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
IQVIA RDS Pty Limited
Query!
Address
Level 8
201 Pacific Highway
St. Leonards
Sydney
NSW 2065
Query!
Country
Australia
Query!
Secondary sponsor category [1]
307499
0
None
Query!
Name [1]
307499
0
Query!
Address [1]
307499
0
Query!
Country [1]
307499
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
307082
0
Health and Disability Ethics Committee
Query!
Ethics committee address [1]
307082
0
Ministry of Health
Health and Disability Ethics Committees
PO Box 5013
Wellington 6140
Query!
Ethics committee country [1]
307082
0
New Zealand
Query!
Date submitted for ethics approval [1]
307082
0
12/10/2020
Query!
Approval date [1]
307082
0
02/11/2020
Query!
Ethics approval number [1]
307082
0
Query!
Summary
Brief summary
This is a Phase 1, Open-label study performed to determine the pharmacokinetics (PK), safety and tolerability and pharmacodynamics (PD) of the study drug, VIS649 solution when administered subcutaneously in healthy non-Japanese and Japanese males and females aged between 18 and 55 years. The assessment will be done in up to 3 dose cohorts. The results will facilitate the treatment of immunoglobulin (Ig) A nephropathy. The study comprises of a screening period up to 30 days before dosing, an in-house stay for approximately 3 days (in which dosing will be done on first day and discharge on second day), followed by a post-administration period of 16 weeks with follow-up visits. The total duration of the clinical study per participant will be up to approximately 20 weeks (5 months), including the screening period. A total of 36 participants (12 in each cohort) will be enrolled with 9 Non-Japanese and 3 Japanese in each cohort. A Safety Monitoring Committee will be used for reviewing safety and tolerability data of the study.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
105970
0
Dr Paul Hamilton
Query!
Address
105970
0
Auckland Clinical Studies Ltd.
ACS House
3 Ferncroft Street
Auckland, New Zealand
1010
Query!
Country
105970
0
New Zealand
Query!
Phone
105970
0
+64 9 373 3474
Query!
Fax
105970
0
Query!
Email
105970
0
[email protected]
Query!
Contact person for public queries
Name
105971
0
Mr Vijaykumar Rajendrakumar Prajapati
Query!
Address
105971
0
IQVIA RDS Pty Ltd.
Level 8, 201 Pacific Highway
St. Leonards, Sydney, NSW 2065
Query!
Country
105971
0
Australia
Query!
Phone
105971
0
+61 2 9016 8100
Query!
Fax
105971
0
Query!
Email
105971
0
[email protected]
Query!
Contact person for scientific queries
Name
105972
0
Dr Asher Schachter
Query!
Address
105972
0
Visterra, Inc.
275 2nd Avenue
Waltham, MA 02451
Query!
Country
105972
0
United States of America
Query!
Phone
105972
0
+1 617 417 9792
Query!
Fax
105972
0
Query!
Email
105972
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
With a single site and limited participants data sharing is not recommended for reasons of patient confidentiality. Also as a small PK study for a specific drug applicability of data is limited.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
Current Study Results
No documents have been uploaded by study researchers.
Update to Study Results
Doc. No.
Type
Is Peer Reviewed?
DOI
Citations or Other Details
Attachment
3884
Basic results
No
380728-(Uploaded-27-01-2024-05-38-56)-Basic results summary.docx
4803
Study results article
Yes
Safety, Pharmacokinetics, and Pharmacodynamics of ...
[
More Details
]
380728-(Uploaded-27-01-2024-05-40-29)-Journal results publication.docx
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Sibeprenlimab in Healthy Participants.
2023
https://dx.doi.org/10.1002/cpdd.1316
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF